Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 2/20 | 0.60 |
| ▸ | FLT3 | P36888 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL914570 | 0.87 | SRD5A2 (0.60) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL914169 | 0.87 | SRD5A2 (0.60) | SRD5A2FLT3NPC1RAB9AMEN1 | |
| SCHEMBL913977 | 0.85 | SRD5A2 (0.57) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL913950 | 0.85 | SRD5A2 (0.65) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL916178 | 0.84 | SRD5A2 (0.55) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL914627 | 0.84 | SRD5A2 (0.55) | SRD5A2FLT3RAB9AMEN1KMT2A | |
| SCHEMBL913502 | 0.82 | SRD5A2 (0.53) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL916236 | 0.82 | SRD5A2 (0.58) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL914148 | 0.80 | SRD5A2 (0.58) | SRD5A2FLT3POLBNPC1RAB9A | |
| SCHEMBL914524 | 0.80 | SRD5A2 (0.58) | SRD5A2FLT3POLBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | claimed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | claimed |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-01-21 | — | — | US | claimed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | claimed |
| EP-2125782-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | Novartis AG (CH) | 2009-12-02 | — | — | EP | claimed |
| WO-2008101905-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | claimed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | claimed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | claimed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | claimed |
| US-8354431-B2 | Aryl carboxylic acid cyclohexyl amide derivatives | NOVARTIS AG (CH) | 2013-01-15 | — | — | US | disclosed |
| US-8183366-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2125782-B1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-08-03 | — | — | EP | disclosed |
| US-20110015180-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2011-01-20 | — | — | US | disclosed |
| US-7858781-B2 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2010-12-28 | — | — | US | disclosed |
| EP-1720859-B1 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| EP-2125782-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101905-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| US-20070155721-A1 | Chemokine receptor antagonists | NOVARTIS AG (CH) | 2007-07-05 | — | — | US | disclosed |
| EP-1720859-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077932-A2 | CHEMOKINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015180-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SRD5A2 849/4885FLT3 225/4885POLB 2951/4885 |
| US-20070155721-A1 | Chemokine receptor antagonists | ACKR3, CXCR2, CXCR4 | SRD5A2 869/4885FLT3 240/4885POLB 2924/4885 |
| US-20100016361-A1 | ARYL CARBOXYLIC ACID CYCLOHEXYL AMIDE DERIVATIVES | CYP2D6, CYP2B6, CYP2C9 | SRD5A2 934/4885FLT3 57/4885POLB 3383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.